Welcome!

News Feed Item

UK Injectables Market Outlook to 2017

NEW YORK, Feb. 17, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

UK Injectables Market Outlook to 2017
http://www.reportlinker.com/p01622848/UK-Injectables-Market-Outlook-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Injectables occupy a considerable prominence in UK irrespective of diminishing growth in the pharmaceutical market for 2-3 years. The advancements in technology up-gradation and investments have provided immense growth opportunities for injectables to emerge in the UK's pharmaceutical industry in recent years. According to RNCOS' research report, "UK Injectables Market Outlook to 2017", the market is anticipated to grow at a CAGR of approximately 4.5% during 2012-2017. The increasing need of injectables for diseases like diabetes, infectious diseases and arthritis is primarily driving this market.

The said report is a study of the UK injectable market in terms of major therapeutic areas. It covers the historical sales trend of injectables for categories such as Diabetes, Vaccines, Sex Hormones & Antagonist in Malign Disease, Anticoagulants & Protamine, Hypothalamic & Pituitary Hormones, Rheumatic Diseases & Gout, etc. Not only this, the report also provides the sales trend of the top 10 injectable drugs in the UK market along with a rational analysis.

Certain pharmaceutical firms in UK's injectable market have established their foothold given the diverse and innovative product offerings. Several small pharma majors too have been aggressively competing with big pharmaceutical players in order to establish themselves in the market. The report highlights a detailed comparison of the market shares of different players in the injectables market.

The study provides an insight about the competitive landscape, which includes business profiling and a strength-weakness analysis of top pharmaceutical players in the UK injectable business. There's also a coverage of the detailed analysis of their top injectable drugs in terms of revenue.

A lot of investment is being done in research and development of injectables in order to improve their medical outcomes. Here it is worth mentioning that even the country's government has significantly contributed towards the development of innovative medicines.

Moreover, the Government has shifted its focus towards cost effective drug treatments by fixing up the drug prices as per their clinical value. In addition, there are a set of regulations that support the injectable drug business in the country. In this context, various regulatory processes such as drug licensing, marketing/ promotion, pricing etc. have been comprehensively covered in the report. In a nutshell, the report covers every aspect of UK injectables which will help the industry players to take strategic decisions.

1. Analyst View

2. Research Methodology

3. UK Injectables Market Outlook to 2017
3.1 Current and Future Market Analysis
3.1.1 By Top 10 Injectables
3.1.2 By Top 10 Therapeutics
3.1.3 By Major Players

4. Drivers and Challenges
4.1 Drivers
4.2 Challenges

5. Regulatory Environment

6. Competitive Landscape
6.1 Novo Nordisk
6.1.1 Business Overview
6.1.2 Key Injectable Sales
6.1.3 Strengths and Weaknesses
6.1.4 Recent Developments
6.2 Sanofi
6.2.1 Business Overview
6.2.2 Key Injectable Sales
6.2.3 Strengths and Weaknesses
6.2.4 Recent Developments
6.3 Eli Lily & Co.
6.3.1 Business Overview
6.3.2 Key Injectable Sales
6.3.3 Strengths and Weaknesses
6.4 Pfizer
6.4.1 Business Overview
6.4.2 Key Injectable Sales
6.4.3 Strengths and Weaknesses
6.4.4 Recent Developments
6.5 Abbott Laboratories
6.5.1 Business Overview
6.5.2 Key Injectable Sales
6.5.3 Strengths and Weaknesses
6.5.4 Recent Developments
6.6 Takeda Pharmaceutical Company Ltd
6.6.1 Business Overview
6.6.2 Key Injectable Sales
6.6.3 Strengths and Weaknesses
6.6.4 Recent Developments

List of Figures:

Figure 3-1: Injectables Market (Million £), 2012-2017
Figure 3-2: Injectables Market by Player (%), 2010
Figure 3-3: Injectables Market by Player (%), 2012
Figure 6-1: Novo Nordisk - Break up of Revenue by Business Segment (%), 2012
Figure 6-2: Novo Nordisk - Diabetes Care Revenue by Segment (%), 2012
Figure 6-3: Novo Nordisk UK - Break up of Revenue by Segment (%), 2012
Figure 6-4: Sanofi - Break up of Revenue by Business Segment (%), 2012
Figure 6-5: Eli Lily & Co. - Break up of Revenue by Business Segment (%), 2012
Figure 6-6: Eli Lily & Co. - Human Pharmaceutical Division Revenue by Segment (%), 2012
Figure 6-7: Pfizer - Break up of Revenue by Business Segment (%), 2012

List of Tables:

Table 3-1: Top 10 Injectable Sales (Million £), 2010-2012
Table 3-2: Injectable Sales by Top 10 Therapeutics (Million £), 2010-2012
Table 6-1: Novo Nordisk UK - Key Injectable Sales (Million £), 2010-2012
Table 6-2: Novo Nordisk UK - Strengths and Weaknesses
Table 6-3: Sanofi UK - Key Injectable Sales (Million £), 2010-2012
Table 6-4: Sanofi UK - Strengths and Weaknesses
Table 6-5: Eli Lily & Co. UK - Key Injectable Sales (Million £), 2010-2012
Table 6-6: Eli Lily & Co. UK - Strengths and Weaknesses
Table 6-7: Pfizer UK - Key Injectable Sales (Million £), 2010-2012
Table 6-8: Pfizer UK - Strengths and Weaknesses
Table 6-9: Abbott Laboratories UK - Key Injectable Sales (Million £), 2010-2012
Table 6-10: Abbott Laboratories UK - Strengths and Weaknesses
Table 6-11: Takeda Pharmaceuticals UK - Key Injectable Sales (Million £), 2010-2012
Table 6-12: Takeda Pharmaceuticals UK - Strengths and Weaknesses

To order this report: UK Injectables Market Outlook to 2017
http://www.reportlinker.com/p01622848/UK-Injectables-Market-Outlook-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his session at @DevOpsSummit at 20th Cloud Expo, Kelly Looney, director of DevOps consulting for Skytap, showed how an incremental approach to introducing containers into complex, distributed applications results in modernization with less risk and more reward. He also shared the story of how Skytap used Docker to get out of the business of managing infrastructure, and into the business of delivering innovation and business value. Attendees learned how up-front planning allows for a clean sep...
Most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes a lot of work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reduction in cost ...
Detecting internal user threats in the Big Data eco-system is challenging and cumbersome. Many organizations monitor internal usage of the Big Data eco-system using a set of alerts. This is not a scalable process given the increase in the number of alerts with the accelerating growth in data volume and user base. Organizations are increasingly leveraging machine learning to monitor only those data elements that are sensitive and critical, autonomously establish monitoring policies, and to detect...
Enterprise architects are increasingly adopting multi-cloud strategies as they seek to utilize existing data center assets, leverage the advantages of cloud computing and avoid cloud vendor lock-in. This requires a globally aware traffic management strategy that can monitor infrastructure health across data centers and end-user experience globally, while responding to control changes and system specification at the speed of today’s DevOps teams. In his session at 20th Cloud Expo, Josh Gray, Chie...
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. Jack Norris reviews best practices to show how companies develop, deploy, and dynamically update these applications and how this data-first...
Intelligent Automation is now one of the key business imperatives for CIOs and CISOs impacting all areas of business today. In his session at 21st Cloud Expo, Brian Boeggeman, VP Alliances & Partnerships at Ayehu, will talk about how business value is created and delivered through intelligent automation to today’s enterprises. The open ecosystem platform approach toward Intelligent Automation that Ayehu delivers to the market is core to enabling the creation of the self-driving enterprise.
"At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We're here to tell the world about our cloud-scale infrastructure that we have at Juniper combined with the world-class security that we put into the cloud," explained Lisa Guess, VP of Systems Engineering at Juniper Networks, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., discussed how these tools can be leveraged to develop a lasting competitive advantage ...
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, discussed how to use Kubernetes to set up a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace. H...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
SYS-CON Events announced today that Massive Networks will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Massive Networks mission is simple. To help your business operate seamlessly with fast, reliable, and secure internet and network solutions. Improve your customer's experience with outstanding connections to your cloud.